APPROVAL NOTICE

OFFICE FOR PROTECTION OF RESEARCH SUBJECTS
2107 Ueberroth Building
169407

DATE: January 23, 2004

TO: Linda J. Sax, Ph.D.
Principal Investigator

FROM: Nancy Levine, Ph.D.
Chair, General Campus Institutional Review Board

RE: UCLA IRB #G00-06-053-11
Approved by Full Committee Review
(Approval Period from 01/23/2004 **through** 01/22/2005)
Cooperative Institutional Research Program (CIRP) Freshman Survey

Please be notified that the UCLA Institutional Review Board (UCLA IRB) has approved the above referenced research project involving human subjects in research. The UCLA's Federalwide Assurance (FWA) with the Department of Health and Human Services, Office for Human Research Protections is FWA00004642.

PLEASE COMPLY WITH THE FOLLOWING CODICIL(S) IMPOSED BY THE HSPC:

1. **The UCLA GC-IRB approved a waiver of the requirement for SIGNED informed consent for the administration of the Cooperative Institutional Research Program (CIRP) Freshman Survey.**

Nancy E Levine

Approval Signature of the UCLA IRB Chair

PRINCIPLES TO BE FOLLOWED BY PRINCIPAL INVESTIGATORS:

As the Principal Investigator, you have ultimate responsibility for the conduct of the study, the ethical performance of the project, the protection of the rights and welfare of human subjects, and strict adherence to any stipulations imposed by the UCLA IRB. You must abide by the following principles when conducting your research:

APPROVAL NOTICE
IRB #G00-06-053-11

1. Perform the project by qualified personnel according to the approved protocol.
2. Do not implement changes in the approved protocol or consent form without prior UCLA IRB approval (except in a life-threatening emergency, if necessary to safeguard the well-being of human subjects.)
3. If written consent is required, obtain the legally effective written informed consent from human subjects or their legally responsible representative using only the currently approved UCLA-IRB stamped consent form.
4. Promptly report all undesirable and unintended, although not necessarily unexpected adverse reactions or events, that are the result of therapy or other intervention, within five working days of occurrence. All fatal or life-threatening events or events requiring hospitalization must be reported to the UCLA IRB in writing within 48 hours after discovery.
5. In clinical medical research, any physician(s) caring for your research subjects must be fully aware of the protocol in which the subject is participating.
6. No subjects may be identified, contacted, recruited, or enrolled until the contract with the sponsor is finalized by the University.

FUNDING SOURCE(S):

According to the information provided in your application, the funding source(s) for this research project may include the following: other (Self Supported).